Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Apr;20(2):209-14.
doi: 10.3346/jkms.2005.20.2.209.

Successful Treatment of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis With HLH-94 Protocol

Affiliations
Free PMC article

Successful Treatment of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis With HLH-94 Protocol

Jin-Seok Lee et al. J Korean Med Sci. .
Free PMC article

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare, fatal disorder of children, affecting predominantly the mononuclear phagocytic system. Previous reports indicate that Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) can also be fatal in many cases, although the prognosis for EBV-HLH is better than for the familial form of hemophagocytic lymphohistiocytosis. We treated four patients with EBV-HLH using immunochemotherapy including steroid, etoposide (VP-16), and cyclosporin, according to the HLH-94 protocol. All patients experienced persistent fever, cytopenia, and hypertriglyceridemia. Serological testing for EBV showed reactivated EBV infections in all patients. EBV DNA detected by PCR and EBV-encoded small RNA measured by in situ hybridization were confirmed in the patients' bone marrow specimens. Hemophagocytosis was shown in bone marrow aspirates and liver biopsy specimen. Complete remission was achieved in all patients after induction and continuation therapy for 4-10 months (median, 7 months) and was maintained for 15-27 months (median, 19 months) without the need for bone marrow transplantation. These results suggest that EBV-HLH can be effectively controlled by immunochemotherapy using the HLH-94 protocol.

Figures

Fig. 1
Fig. 1
Detection of EBV genomic DNA from bone marrow cells of patients with EBV-HLH by PCR (size of PCR product; 139 bp).
Fig. 2
Fig. 2
EBER expression was identified in nuclei of bone marrow cells by mRNA in situ hybridization using specific EBERs cDNA oligonucleotide probe (A, ×200; B, ×400).
Fig. 3
Fig. 3
The smear of bone marrow aspirate showed histiocyte (H) with phagocytosis of RBC (R), platelet (PL) and neutrophil (N) (Wright stain, ×1,000)

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Imashuku S, Hibi S, Ohara T, Iwai A, Sako M, Kato M, Arakawa H, Sotomatsu M, Kataoka S, Asami K, Hasegawa D, Kosaka Y, Sano K, Igarashi N, Maruhashi K, Ichimi R, Kawasaki H, Maeda N, Tanizawa A, Arai K, Abe T, Hisakawa H, Miyashita H, Henter JI. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood. 1999;93:1869–1874. - PubMed
    1. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367–2373. - PubMed
    1. Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, Ladisch S, Webb D. HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 1997;28:342–347. - PubMed
    1. Henter JI, Elinder G, Ost A. Diagnosis guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991;18:29–33. - PubMed
    1. Ladisch S. Histiocytosis syndrome of childhood. In: Behrman RE, Kliegman RM, Jenson HB, editors. Nelson Textbook of Pediatrics. 17th ed. Philadelphia: W.B. Saunders Co; 2003. pp. 1727–1730.

Publication types

Feedback